ASCO Abstracts 2020

ASCO Abstracts

ASCO: Phase III QUAZAR AML-001 trial

Abstract No : 7530

Abstract Type : Poster Discussion Session

Indication : Acute Myeloid Leukemia

Intervention : CC-486

Company : BMS

Technology : Small molecule

CC-486 is safe and well-tolerated as maintenance therapy in elderly patients ($75 years) with acute myeloid leukemia (AML) in first remission following induction chemotherapy: Results from the phase III QUAZAR AML-001 trial.

ASCO: KEYNOTE-189 study

Abstract No : 9582

Abstract Type : Poster Session

Indication : Nonsquamous NSCLC

Intervention : Pemetrexed-platinum chemotherapy (chemo) with or without pembrolizumab (pembro)

Company : Merck Sharp & Dohme Corp.

Technology : Monoclonal antibody

Final data of KEYNOTE-189 study in patients with newly diagnosed metastatic nonsquamous NSCLC

ASCO: Initial KarMMa results

Abstract No : 8503

Abstract Type : Oral Abstract Session

Indication : Multiple Myeloma

Intervention : Idecabtagene vicleucel

Company : Bristol-Myers Squibb and bluebird bio.

Technology : CAR T Cell Therapy

Idecabtagene vicleucel (ide-cel; bb2121), a BCMA-targeted CAR T-cell therapy, in patients with relapsed and refractory multiple myeloma (RRMM): Initial KarMMa results

Anti-cd47 Antibody Magrolimab Combined With Azacitidine

Abstract No : 7507

Abstract Type : Poster Discussion Session

Indication : MDS/AML

Intervention : Magrolimab

Company : Forty Seven, Inc

Technology : Monoclonal antibody

Tolerability and efficacy of the first-in-class anti-CD47 antibody magrolimab combined with azacitidine in MDS and AML patients: Phase Ib results